MirimGENE has been selected as an official nominee in the Best Startup category at Prix Galien Korea 2026.
The Prix Galien is an international awards program celebrating innovative medicines and medical technologies that contribute to human health. Held in Korea for the first time in 2026, the program named MirimGENE among its official nominees for its WITheranostics™ platform.
WITheranostics™ is a platform under development that connects diagnosis and treatment for intractable inflammatory and immune-mediated diseases by targeting WARS1, a key mediator of inflammatory responses. Through this approach, MirimGENE is exploring new therapeutic strategies to address the limitations of existing treatments.
Building on this nomination, MirimGENE remains committed to advancing its research and development to bring new treatment possibilities to patients with intractable inflammatory and immune-mediated diseases.